R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients

References

• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Dybkaer K, Bogsted M, Falgreen S, et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol. 2015;33:1379–1388.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer. 2013;109:312–317.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503–507.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000.
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41:595–611.
   PubMed Web of Science ®Google Scholar
• Oleksik AM, Ewing S, Shen W, et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int. 2005;16:861–870.
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515–1526.
   PubMed Web of Science ®Google Scholar
• Lee S, Chung CK, Oh SH, et al. Correlation between bone mineral density measured by dual-energy X-ray absorptiometry and Hounsfield units measured by diagnostic CT in lumbar spine. J Korean Neurosurg Soc. 2013;54:384–389.
   PubMed Web of Science ®Google Scholar
• Romme EA, Murchison JT, Phang KF, et al. Bone attenuation on routine chest CT correlates with bone mineral density on DXA in patients with COPD. J Bone Miner Res. 2012;27:2338–2343.
   PubMed Web of Science ®Google Scholar
• Schreiber JJ, Anderson PA, Rosas HG, et al. Hounsfield units for assessing bone mineral density and strength: a tool for osteoporosis management. J Bone Joint Surg Am. 2011;93:1057–1063.
   PubMed Web of Science ®Google Scholar
• Marinova M, Edon B, Wolter K, et al. Use of routine thoracic and abdominal computed tomography scans for assessing bone mineral density and detecting osteoporosis. Curr Med Res Opin. 2015;31:1871–1881.
   PubMed Web of Science ®Google Scholar
• Pickhardt PJ, Pooler BD, Lauder T, et al. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Ann Intern Med. 2013;158:588–595.
   PubMed Web of Science ®Google Scholar
• Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–1148.
   PubMed Web of Science ®Google Scholar
• Pompe E, Willemink MJ, Dijkhuis GR, et al. Intravenous contrast injection significantly affects bone mineral density measured on CT. Eur Radiol. 2015;25:283–289.
   PubMed Web of Science ®Google Scholar
• Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191–192.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–787.
   PubMed Web of Science ®Google Scholar
• Woolf AD. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2007;19:370–375.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274–282.
   PubMed Web of Science ®Google Scholar
• Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013;1:59–70.
   PubMed Web of Science ®Google Scholar
• Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570–1593.
   PubMed Web of Science ®Google Scholar
• Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39:1403–1409.
   PubMed Web of Science ®Google Scholar
• Anasti JN, Kalantaridou SN, Kimzey LM, et al. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1998;91:12–15.
   PubMed Web of Science ®Google Scholar
• Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202–211.
   PubMed Web of Science ®Google Scholar
• Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res. 2002;17:1512–1526.
   PubMed Web of Science ®Google Scholar
• Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009;36:1705–1714.
   PubMed Web of Science ®Google Scholar
• Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89:4923–4928.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Lu H, Fang S, et al. Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma. 2007;48:1514–1521.
   PubMed Web of Science ®Google Scholar
• Brown JE, Ellis SP, Silcocks P, et al. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res. 2006;12:6480–6486.
   PubMed Web of Science ®Google Scholar
• Paccou J, Merlusca L, Henry-Desailly I, et al. Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study. Ann Oncol. 2014;25:481–486.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int. 2005;16:134–141.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lim SK, Hahn JS. Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. Am J Med. 2004;116:524–528.
   PubMed Web of Science ®Google Scholar
• Westin JR, Thompson MA, Cataldo VD, et al. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013;13:99–105.
   PubMed Web of Science ®Google Scholar
• Alsyouf M, Smith DL, Olgin G, et al. Comparing stone attenuation in low- and conventional-dose noncontrast computed tomography. J Endourol. 2014;28:704–707.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Wahner HW, Seeman E, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest. 1982;70:716–723.
   PubMed Web of Science ®Google Scholar
• Schreiber JJ, Anderson PA, Hsu WK. Use of computed tomography for assessing bone mineral density. Neurosurg Focus. 2014;37:E4.
   PubMed Web of Science ®Google Scholar